Organigram Global Inc. (OGI)
NASDAQ: OGI · Real-Time Price · USD
1.570
0.00 (0.00%)
At close: Dec 2, 2025, 4:00 PM EST
1.600
+0.030 (1.91%)
After-hours: Dec 2, 2025, 7:16 PM EST
Organigram Global Revenue
Organigram Global had revenue of 70.79M CAD in the quarter ending June 30, 2025, with 72.41% growth. This brings the company's revenue in the last twelve months to 223.82M, up 50.01% year-over-year. In the fiscal year ending September 30, 2024, Organigram Global had annual revenue of 159.84M with 7.13% growth.
Revenue (ttm)
223.82M CAD
Revenue Growth
+50.01%
P/S Ratio
1.29
Revenue / Employee
249,243 CAD
Employees
898
Market Cap
212.17M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 159.84M | 10.64M | 7.13% |
| Sep 30, 2023 | 149.21M | 3.40M | 2.33% |
| Aug 31, 2022 | 145.81M | 66.65M | 84.19% |
| Aug 31, 2021 | 79.16M | -7.63M | -8.79% |
| Aug 31, 2020 | 86.80M | 6.38M | 7.94% |
| Aug 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
OGI News
- 7 days ago - Organigram Announces Appointment of Chief Executive Officer - Business Wire
- 9 days ago - Sell Village Farms And Buy Organigram - Seeking Alpha
- 18 days ago - 4 Cannabis Stocks Log Momentum Gains Even As Congress Re-Criminalizes Some THC Products In Spending Bill - Benzinga
- 4 weeks ago - Majority of Canadians Want Carney Government to Catch Up on Cannabis Policy - Business Wire
- 6 weeks ago - Organigram Global Announces Update to CEO Succession Plan - Business Wire
- 6 weeks ago - 3 Canadian Cannabis Stocks to Watch as U.S. Legalization Gains Steam in 2025 - MarijuanaStocks
- 7 weeks ago - Organigram Global Launches happly, a New U.S. Hemp-Derived THC Brand Offering Targeted Formulations for Three Mood States; Socialize, Relax, and Sleep - Business Wire
- 2 months ago - OrganiGram (OGI) Joins Cannabis Stock Rally After Trump Signals Policy Shift - Benzinga